Market News How it works Learn FAQ
| TGL 0.2897 30.79% | SRTM 0.6164 43.25% | NU 11.845 -21.87% | GCDT 0.1604 -8.92% | EWZ 31.98 -24.91% | NWGL 0.0808 -1.46% | SHFS 0.1254 -5.29% | RBNE 0.183 -3.68% | CLRO 4.2705 31.40% | SPRC 1.635 50.00% | SOXL 87.29 4.46% | BBD 2.9088 -28.53% | VBIO 0.785 -16.49% | RENT 2.85 23.91% | ITUB 7.63 -21.10% | PBR 21.675 -17.14% | SOXS 50.2 -4.31% | TSLL 10.68 9.43% | SPCX 147.12 -0.25% | XP 14.42 -52.58% | XXII 0.1032 -47.80% | GPUS 0.1583 -6.28% | WFF 0.0741 -7.38% | KORU 10.59 0.09% | CRWV 52.0841 -3.97% | IREN 24.13 -3.11% | STNE 7.83 -31.79% | SQQQ 39.02 -1.66% | PRSO 0.35 -7.51% | NOK 8.44 3.69% | INTR 4.751 -33.92% | MYND 0.2219 -7.54% | TQQQ 67.37 1.63% | INTC 88.11 1.32% | VALE 12.27 -1.05% | NVDA 214.88 1.86% | TSLA 389.99 4.77% | VZ 43.45 -2.71% | IBIT 44.9769 -2.14% | WORX 2.2101 0.92% | YMAT 2.25 9.76% | AZTR 0.9102 1,173.01% | JBLU 2.4312 -7.38% | STLA 4.105 1.11% | WULF 11.36 0.35% | T 21.075 0.69% | IRE 2.9 -6.15% | PAGS 8.6 -24.83% | META 631.35 -1.75% | NBIS 151.07 -4.83%
ALAllarity Therapeutics, Inc. logo

Allarity Therapeutics, Inc. (ALLR)

NASDAQ Global Market · Currency in USD
$0.89 ▲ +0.02 (+2.84%)
As of Oct 26, 10:15 AM ET. Market open.

Summary

Previous Close
$0.87
Open
$0.88
Day's Range
$0.87 – $0.92
52 Week Range
$0.77 – $1.84
Volume
61,507
Avg. Volume
109,767
Market Cap
$14.16M
Beta (5Y Monthly)
0.57
PE Ratio (TTM)
--
EPS (TTM)
-$0.78
Earnings Date
Nov 13, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Allarity Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
8
CEO
Thomas H. Jensen

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer.

Earnings

Next report: Fri, Nov 13, 2026
EPS estimate -$0.21
DateEst.Actual
Aug 14, 2026-$0.25-$0.21Beat
May 15, 2026-$0.22-$0.17Beat
Mar 31, 2026-$0.22-$0.19Beat
Nov 14, 2025-$0.23-$0.19Beat
Aug 15, 2025-$0.21-$0.15Beat
May 9, 2025–-$0.25

Analyst view

Rating: Buy
Buy 50% · Hold 50% · Sell 0%

Get free alerts on ALLR and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.